Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology

Biomedicines - Tập 10 Số 5 - Trang 1012
Gabriela Elena Lupusoru1,2, Ioana Ailincăi1,2, Georgiana Frățilă1,2, Oana Ungureanu1,2, Andreea Andronesi1,2, Mircea Lupușoru3, Mihaela Banu4, Ileana Adela Văcăroiu1,5, Constantin Dina6, I. Sinescu7,1
1Department of Nephrology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
2Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania
3Department of Physiology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
4Department of Anatomy, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
5Department of Nephrology, Sf Ioan Clinical Emergency Hospital, 042122 Bucharest, Romania
6Department of Anatomy, Ovidius University, 900527 Constanța, Romania
7Center for Uronephrology and Kidney Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania

Tóm tắt

Tumor lysis syndrome (TLS) is a common cause of acute kidney injury in patients with malignancies, and it is a frequent condition for which the nephrologist is consulted in the case of the hospitalized oncological patient. Recognizing the patients at risk of developing TLS is essential, and so is the prophylactic treatment. The initiation of treatment for TLS is a medical emergency that must be addressed in a multidisciplinary team (oncologist, nephrologist, critical care physician) in order to reduce the risk of death and that of chronic renal impairment. TLS can occur spontaneously in the case of high tumor burden or may be caused by the initiation of highly efficient anti-tumor therapies, such as chemotherapy, radiation therapy, dexamethasone, monoclonal antibodies, CAR-T therapy, or hematopoietic stem cell transplantation. It is caused by lysis of tumor cells and the release of cellular components in the circulation, resulting in electrolytes and metabolic disturbances that can lead to organ dysfunction and even death. The aim of this paper is to review the scientific data on the updated definition of TLS, epidemiology, pathogenesis, and recognition of patients at risk of developing TLS, as well as to point out the recent advances in TLS treatment.

Từ khóa


Tài liệu tham khảo

Andronesi, 2021, Renal Replacement Therapy in Cancer Patients with Acute Kidney Injury (Review), Exp. Ther. Med., 22, 864, 10.3892/etm.2021.10296

Finkel, K.M., Perazella, M.A., and Cohen, E.P. (2020). Tumor Lysis Syndrome. Onco-Nephrology, Elsevier Inc.

Howard, 2011, The Tumor Lysis Syndrome, N. Eng. J. Med., 364, 1844, 10.1056/NEJMra0904569

Younes, 2010, Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and Management, Am. J. Kidney Dis., 55, S1, 10.1053/j.ajkd.2009.10.056

Malyszko, 2020, Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress, Kidney Blood Press. Res., 45, 645, 10.1159/000509934

Montesinos, 2008, Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia: Identification of Risk Factors and Development of a Predictive Model, Haematologica, 93, 67, 10.3324/haematol.11575

Wilson, 2012, Onco-Nephrology: Tumor Lysis Syndrome, Clin. J. Am. Soc. Nephrol., 7, 1730, 10.2215/CJN.03150312

McDonnell, 2008, Fatal Peri-Operative Acute Tumour Lysis Syndrome Precipitated by Dexamethasone, Anaesthesia, 63, 652, 10.1111/j.1365-2044.2007.05436.x

Furtado, 2008, Bortezomib-Associated Tumor Lysis Syndrome in Multiple Myeloma, Leuk. Lymphoma, 49, 2380, 10.1080/10428190802484099

Lipstein, 2010, Bortezomib-Induced Tumor Lysis Syndrome in a Patient with HIV-Negative Plasmablastic Lymphoma, Clin. Lymphoma Myeloma Leuk., 10, E43, 10.3816/CLML.2010.n.074

Fuente, 2004, Tumor Lysis Syndrome in a Multiple Myeloma Treated with Thalidomide, Ann. Oncol., 15, 537, 10.1093/annonc/mdh116

Lee, 2006, Acute Tumor Lysis Syndrome after Thalidomide Therapy in Advanced Hepatocellular Carcinoma, Oncologist, 11, 87, 10.1634/theoncologist.11-1-87

Francescone, 2009, Tumor Lysis Syndrome Occurring after the Administration of Rituximab for Posttransplant Lymphoproliferative Disorder, Transplant. Proc., 41, 1946, 10.1016/j.transproceed.2009.03.060

Noh, 2008, Fatal Tumor Lysis Syndrome during Radiotherapy for Non–Small-Cell Lung Cancer, J. Clin. Oncol., 26, 6005, 10.1200/JCO.2008.19.4308

Fleming, 1991, Radiation Induced Acute Tumor Lysis Syndrome in the Bone Marrow Transplant Setting, Bone Marrow Transplant., 8, 235

Farooq, 2009, Tumor Lysis Syndrome after Starting Treatment with Gleevec in a Patient with Chronic Myelogenous Leukemia, J. Clin. Pharm. Ther., 34, 607, 10.1111/j.1365-2710.2009.01035.x

Hsieh, 2009, Tumor Lysis Syndrome after Transarterial Chemoembolization of Hepatocellular Carcinoma: Case Reports and Literature Review, World J. Gastroenterol., 15, 4726, 10.3748/wjg.15.4726

Simmons, 1991, Acute Tumor Lysis Syndrome after Intrathecal Methotrexate Administration, Cancer, 67, 2062, 10.1002/1097-0142(19910415)67:8<2062::AID-CNCR2820670809>3.0.CO;2-U

Hande, 1993, Acute Tumor Lysis Syndrome in Patients with High-Grade Non-Hodgkin’s Lymphoma, Am. J. Med., 94, 133, 10.1016/0002-9343(93)90174-N

Cairo, 2004, Tumour Lysis Syndrome: New Therapeutic Strategies and Classification, Br. J. Haematol., 127, 3, 10.1111/j.1365-2141.2004.05094.x

Mehta, 2007, Acute Kidney Injury Network: Report of an Initiative to Improve Outcomes in Acute Kidney Injury, Crit. Care, 11, R31, 10.1186/cc5713

Shimada, 2009, A Novel Role for Uric Acid in Acute Kidney Injury Associated with Tumour Lysis Syndrome, Nephrol. Dial. Transplant., 24, 2960, 10.1093/ndt/gfp330

Conger, 1977, Intrarenal Dynamics in the Pathogenesis and Prevention of Acute Urate Nephropathy, J. Clin. Investig., 59, 786, 10.1172/JCI108700

Kang, 2005, Uric Acid–Induced C-Reactive Protein Expression: Implication on Cell Proliferation and Nitric Oxide Production of Human Vascular Cells, J. Am. Soc. Nephrol., 16, 3553, 10.1681/ASN.2005050572

Cirillo, 2009, Ketohexokinase-Dependent Metabolism of Fructose Induces Proinflammatory Mediators in Proximal Tubular Cells, J. Am. Soc. Nephrol., 20, 545, 10.1681/ASN.2008060576

Han, 2007, Uric Acid Inhibits Renal Proximal Tubule Cell Proliferation via at Least Two Signaling Pathways Involving PKC, MAPK, CPLA2, and NF-ΚB, Am. J. Physiol. Ren. Physiol., 292, F373, 10.1152/ajprenal.00104.2006

Larson, R.A., and Pui, C.-H. (2020, March 15). Tumor Lysis Syndrome: Definition, Pathogenesis, Clinical Manifestations, Etiology and Risk Factors. Available online: https://www.uptodate.com/contents/tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors.

Riccio, 2006, Spontaneous Tumor Lysis Syndrome in Acute Myeloid Leukemia: Two Cases and a Review of the Literature, Cancer Biol. Ther., 5, 1614, 10.4161/cbt.5.12.3610

Agnani, 2005, Marked Hyperuricemia with Acute Renal Failure: Need to Consider Occult Malignancy and Spontaneous Tumour Lysis Syndrome, Int. J. Clin. Pract., 60, 364, 10.1111/j.1742-1241.2005.00623.x

Hsu, 2004, Neglected Cause of Renal Failure in Cancer Patients: Spontaneous Tumor Lysis Syndrome Inducing Acute Uric Acid Nephropathy, Dial. Transplant., 33, 316

Filippatos, 2005, Alterations in Electrolyte Equilibrium in Patients with Acute Leukemia, Eur. J. Haematol., 75, 449, 10.1111/j.1600-0609.2005.00547.x

Dunlay, 1989, Calcitriol in Prolonged Hypocalcemia Due to the Tumor Lysis Syndrome, Ann. Intern. Med., 110, 162, 10.7326/0003-4819-110-2-162

Andronesi, 2019, Incidence and Risk Factors for Acute Kidney Injury Following Autologous Stem Cell Transplantation for Multiple Myeloma, Cancer Med., 8, 3278, 10.1002/cam4.2187

Annemans, 2003, Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin’s Lymphoma in Four European Countries, Leuk. Lymphoma, 44, 77, 10.1080/1042819021000054661

Bahoush, 2015, Identification of Children with Acute Lymphoblastic Leukemia at Low Risk for Tumor Lysis Syndrome, J. Blood Disord. Transfus., 6, 2

Ejaz, A.A., Pourafshar, N., Mohandas, R., Smallwood, B.A., Johnson, R.J., and Hsu, J.W. (2015). Uric Acid and the Prediction Models of Tumor Lysis Syndrome in AML. PLoS ONE, 10.

Krishnan, 2008, Cetuximab-Related Tumor Lysis Syndrome in Metastatic Colon Carcinoma, J. Clin. Oncol., 26, 2406, 10.1200/JCO.2007.14.7603

Keane, 2009, Catastrophic Tumour Lysis Syndrome Following Single Dose of Imatinib, Eur. J. Haematol., 82, 244, 10.1111/j.1600-0609.2008.01186.x

Michels, 2010, Sunitinib Inducing Tumor Lysis Syndrome in a Patient Treated for Renal Carcinoma, Investig. New Drugs, 28, 690, 10.1007/s10637-009-9275-z

Baeksgaard, 2003, Acute Tumor Lysis Syndrome in Solid Tumors—a Case Report and Review of the Literature, Cancer Chemother. Pharmacol., 51, 187, 10.1007/s00280-002-0556-x

Cairo, 2010, Recommendations for the Evaluation of Risk and Prophylaxis of Tumour Lysis Syndrome (TLS) in Adults and Children with Malignant Diseases: An Expert TLS Panel Consensus, Br. J. Haematol., 149, 578, 10.1111/j.1365-2141.2010.08143.x

Coiffier, 2008, Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review, J. Clin. Oncol., 26, 2767, 10.1200/JCO.2007.15.0177

Schrappe, 2003, Incidence of Tumor Lysis Syndrome in Children with Advanced Stage Burkitt’s Lymphoma/Leukemia before and after Introduction of Prophylactic Use of Urate Oxidase, Ann. Hematol., 82, 160, 10.1007/s00277-003-0608-2

Mato, 2006, A Predictive Model for the Detection of Tumor Lysis Syndrome during AML Induction Therapy, Leuk. Lymphoma, 47, 877, 10.1080/10428190500404662

Truong, 2007, Features of Presentation Predict Children with Acute Lymphoblastic Leukemia at Low Risc for Tumor Lysis Syndrome, Cancer, 110, 1832, 10.1002/cncr.22990

Belay, 2017, Tumor Lysis Syndrome in Patients with Hematological Malignancies, J. Oncol., 2017, 9684909, 10.1155/2017/9684909

Kaur, 2014, Ibrutinib-Associated Tumor Lysis Syndrome in a Patient with Chronic Lymphocytic Leukemia, Blood, 124, 3503, 10.1182/blood-2014-08-591875

Jones, 2015, Guidelines for the Management of Tumour Lysis Syndrome in Adults and Children with Haematological Malignancies on Behalf of the British Committee for Standards in Haematology, Br. J. Haematol., 169, 661, 10.1111/bjh.13403

Williams, 2019, Tumor Lysis Syndrome, Arch. Pathol. Lab. Med., 143, 386, 10.5858/arpa.2017-0278-RS

Bellinghieri, 2005, Pharmacological Treatment of Acute and Chronic Hyperuricemia in Kidney Diseased Patients, Contrib. Nephrol., 149, 149

Arellano, 1993, Allopurinol Hypersensitivity Syndrome: A Review, Ann. Pharmacother., 27, 337, 10.1177/106002809302700317

Morales, 2001, Relation between Adverse Events Associated with Allopurinol and Renal Function in Renal Patients with Gout, Ann. Rheumatol. Dis., 60, 981, 10.1136/ard.60.10.981

Hung, 2005, HLA-B*5801 Allele as a Genetic Marker for Severe Cutaneous Adverse Reactions Caused by Allopurinol, Proc. Natl. Acad. Sci. USA, 102, 4134, 10.1073/pnas.0409500102

Spina, 2015, Florence: A Randomised, Double Blind, Phase III Pivotal Study of Febuxostat versus Allopurinol for the Prevention of Tumor Lysis Syndrome (TLS) in Patients with Hematologic Malignancies at Intermediate to High TLS Risc, Ann. Oncol., 26, 2155, 10.1093/annonc/mdv317

Kishimoto, 2017, Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies, Anticancer Res., 37, 5845

Bellos, 2019, Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis, J. Clin. Pharm. Ther., 44, 525

Edeani, A., and Shirali, A. (2020, March 15). Tumor Lysis Syndrome. Available online: https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter4.pdf.

Jeha, 2005, Efficacy and Safety of Rasburicase, a Recombinant Urate Oxidase (Elitek t), in the Management of Malignancy-Associated Hyperuricemia in Pediatric and Adult Patients: Final Results of a Multicenter Compassionate Use Trial, Leukemia, 19, 34, 10.1038/sj.leu.2403566

Cortes, 2010, Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study, J. Clin. Oncol., 28, 4207, 10.1200/JCO.2009.26.8896

Gopakumar, 2017, Treatment of Tumor Lysis Syndrome in Children with Leukemia/Lymphoma in Resource-Limited Settings—Efficacy of a Fixed Low-Dose Rasburicase, Pediatr. Hematol. Oncol., 34, 206, 10.1080/08880018.2017.1348415

Kikuchi, 2009, A Study of Rasburicase for the Management of Hyperuricemia in Pediatric Patients with Newly Diagnosed Hematologic Malignancies at High Risk for Tumor Lysis Syndrome, Int. J. Hematol., 90, 492, 10.1007/s12185-009-0402-6

Fayad, 2012, A Randomized Trial of a Single-Dose Rasburicase versus Five-Daily Doses in Patients at Risk for Tumor Lysis Syndrome, Ann. Oncol., 23, 1640, 10.1093/annonc/mdr490

2010, Rasburicasa versus Alopurinol Como Tratamiento de La Hiperuricemia En El Síndrome de Lisis Tumoral [Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome], An. Pediatr., 72, 103, 10.1016/j.anpedi.2009.10.011

Wang, 2006, Recombinant Urate Oxidase (Rasburicase) for the Prevention and Treatment of Tumor Lysis Syndrome in Patients with Hematologic Malignancies, Acta Haematol., 115, 35, 10.1159/000089463

Galardy, 2013, Rasburicase in the Prevention of Laboratory/Clinical Tumour Lysis Syndrome in Children with Advanced Mature B-NHL: A Children’s Oncology Group Report, Br. J. Haematol., 163, 365, 10.1111/bjh.12542

Goldman, 2001, A Randomized Comparison between Rasburicase and Allopurinol in Children with Lymphoma or Leukemia at High Risk for Tumor Lysis, Blood, 97, 2998, 10.1182/blood.V97.10.2998

Digumarti, 2014, Efficacy of Rasburicase (Recombinant Urate Oxidase) in the Prevention and Treatment of Malignancy-Associated Hyperuricemia: An Indian Experience, Indian J. Cancer, 51, 180, 10.4103/0019-509X.138299

Bosly, 2003, Rasburicase (Recombinant Urate Oxidase) for the Management of Hyperuricemia in Patients with Cancer, Cancer, 98, 1048, 10.1002/cncr.11612

Vachhani, 2021, A Phase 2 Trial of Single Low Doses of Rasburicase for Treatment of Hyperuricemia in Adult Patients with Acute Leukemia, Leuk. Res., 107, 106588, 10.1016/j.leukres.2021.106588

Udvardi, 2007, Prevention and Treatment of Hyperuricemia with Rasburicase in Children with Leukemia and Non-Hodgkin’s Lymphoma, Pathol. Oncol. Res., 13, 57, 10.1007/BF02893442

Coiffier, 2003, Efficacy and Safety of Rasburicase (Recombinant Urate Oxidase) for the Prevention and Treatment of Hyperuricemia during Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude Des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study, J. Clin. Oncol., 21, 4402, 10.1200/JCO.2003.04.115

Shin, 2006, Recombinant Urate Oxidase (Rasburicase) for the Treatment of Hyperuricemia in Pediatric Patients with Hematologic Malignancies: Results of a Compassionate Prospective Multicenter Study in Korea, Pediatr. Blood Cancer, 46, 439, 10.1002/pbc.20555

Malaguarnera, 2009, A Single Dose of Rasburicase in Elderly Patients with Hyperuricaemia Reduces Serum Uric Acid Levels and Improves Renal Function, Expert Opin. Pharmacother., 10, 737, 10.1517/14656560902781972

Browning, 2005, Hemolysis and Methemoglobinemia Secondary to Rasburicase Administration, Ann. Pharmacother., 39, 1932, 10.1345/aph.1G272

Finkel, K.W., and Howard, S.C. (2014). Tumor Lysis Syndrome. Renal Diseases in Cancer Patients, Academic Press.

Galoian, 2015, Restoration of Desmosomal Junction Protein Expression and Inhibition of H3K9-Specific Histone Demethylase Activity by Cytostatic Proline-Rich Polypeptide-1 Leads to Suppression of Tumorigenic Potential in Human Chondrosarcoma Cells, Mol. Clin. Oncol., 3, 171, 10.3892/mco.2014.445

Rusu, 2013, Zipper-like Series of Desmosomes Supported by Subplasmalemmal Actin Belts in Thymic Epithelial Reticular Cells in the Rat, Ann. Anat.-Anat., 195, 359, 10.1016/j.aanat.2013.02.007

Chidgey, 1997, Histology and Histopathology from Cell Biology to Tissue Engineering Desmosomes and Disease, Histol. Histopathol., 12, 1159

Wang, 2019, Tumor Lysis Syndrome Associated with Urothelial Cancer: A Case Series, Arch. Clin. Case Stud., 1, 515, 10.33552/ACCS.2019.01.000515

Mirrakhimov, 2014, Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature, Rare Tumors, 6, 68, 10.4081/rt.2014.5389

Pierzynowska, 2020, Oral Treatment with an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice, Front. Med., 24, 569215, 10.3389/fmed.2020.569215

(2022, April 01). ClinicalTrials.gov, Available online: https://clinicaltrials.gov/ct2/show/NCT04745910.

Thông tin
Thông tin xuất bản

Biomedicines

Tập 10 Số 5

1012

Thông tin tác giả